D.E. Shaw & Co
SURF

D.E. Shaw & Co’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

D.E. Shaw & Co’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,605
Closed -$176K – 5106
2021
Q1 		$176K Sell
22,605
-27,074
-54% -$271K ﹤0.01% 3872
2020
Q4 		$459K Buy
+49,679
New +$432K ﹤0.01% 3429

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's SURF Position: Q2 2021 in Review

D.E. Shaw & Co sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2021, closing a stake of 22,605 shares — an estimated $176K sold.

D.E. Shaw & Co first reported a position in SURF in Q4 2020 and held it in 2 quarters. The position peaked at $459K in Q4 2020. 96 funds tracked by Wall St. Rank hold SURF as of Q2 2021.

  • D.E. Shaw & Co reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 22,605 Surface Oncology, Inc. Common Stock shares in Q2 2021, an estimated $176K.
  • D.E. Shaw & Co first reported a position in Surface Oncology, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • D.E. Shaw & Co's Surface Oncology, Inc. Common Stock position peaked at $459K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2021.

Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.